Literature DB >> 21111791

The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord.

J Mika1, E Rojewska, W Makuch, M Korostynski, S Luvisetto, S Marinelli, F Pavone, B Przewlocka.   

Abstract

Botulinum neurotoxin serotype A (BoNT/A) acts by cleaving synaptosome-associated-protein-25 (SNAP-25) in nerve terminals to inhibit neuronal release and shows long-lasting antinociceptive action in neuropathic pain. However, its precise mechanism of action remains unclear. Our study aimed to characterize BoNT/A-induced neuroimmunological changes after chronic constriction injury (CCI) of the sciatic nerve. In the ipsilateral lumbar spinal cords of CCI-exposed rats, the mRNA of microglial marker (complement component 1q, C1q), astroglial marker (glial fibrillary acidic protein, GFAP), and prodynorphin were upregulated, as measured by reverse transcription-polymerase chain reaction (RT-PCR). No changes appeared in mRNA for proenkephalin, pronociceptin, or neuronal and inducible nitric oxide synthase (NOS1 and NOS2, respectively). In the dorsal root ganglia (DRG), an ipsilateral upregulation of prodynorphin, pronociceptin, C1q, GFAP, NOS1 and NOS2 mRNA and a downregulation of proenkephalin mRNA were observed. A single intraplantar BoNT/A (75 pg/paw) injection induced long-lasting antinociception in this model. BoNT/A diminished the injury-induced ipsilateral spinal upregulation of C1q mRNA. In the ipsilateral DRG a significant decrease of C1q-positive cell activation and of the upregulation of prodynorphin, pronociceptin and NOS1 mRNA was also observed following BoNT/A admistration. BoNT/A also diminished the injury-induced upregulation of SNAP-25 expression in both structures. We provide evidence that BoNT/A impedes injury-activated neuronal function in structures distant from the injection site, which is demonstrated by its influence on NOS1, prodynorphin and pronociceptin mRNA levels in the DRG. Moreover, the silence of microglia/macrophages after BoNT/A administration could be secondary to the inhibition of neuronal activity, but this decrease in neuroimmune interactions could be the key to the long-lasting BoNT/A effect on neuropathic pain. Copyright Â
© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111791     DOI: 10.1016/j.neuroscience.2010.11.040

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

Review 1.  Botulinum toxin type A in motor nervous system: unexplained observations and new challenges.

Authors:  I Matak; Z Lacković; M Relja
Journal:  J Neural Transm (Vienna)       Date:  2016-09-01       Impact factor: 3.575

2.  The Use of Botulinum Toxin in the Management of Headache Disorders.

Authors:  Hsiangkuo Yuan; Stephen D Silberstein
Journal:  Handb Exp Pharmacol       Date:  2021

Review 3.  Targeting cytokines for treatment of neuropathic pain.

Authors:  Alice L Hung; Michael Lim; Tina L Doshi
Journal:  Scand J Pain       Date:  2017-08-24

4.  Melatonin Suppresses Neuropathic Pain via MT2-Dependent and -Independent Pathways in Dorsal Root Ganglia Neurons of Mice.

Authors:  Jia-Ji Lin; Ye Lin; Tian-Zhi Zhao; Chun-Kui Zhang; Ting Zhang; Xiao-Li Chen; Jia-Qi Ding; Ting Chang; Zhuo Zhang; Chao Sun; Dai-Di Zhao; Jun-Lin Zhu; Zhu-Yi Li; Jin-Lian Li
Journal:  Theranostics       Date:  2017-05-12       Impact factor: 11.556

5.  Subcutaneous BoNT/A Injection for Intractable Pain and Disability in Complex Regional Pain Syndrome: A Case Report.

Authors:  Yan Tereshko; Chiara Dalla Torre; Christian Lettieri; Enrico Belgrado; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Toxins (Basel)       Date:  2022-06-16       Impact factor: 5.075

Review 6.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

7.  Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.

Authors:  Ann T Hanna-Mitchell; Amanda S Wolf-Johnston; Stacey R Barrick; Anthony J Kanai; Michael B Chancellor; William C de Groat; Lori A Birder
Journal:  Neurourol Urodyn       Date:  2013-10-26       Impact factor: 2.696

Review 8.  Botulinum neurotoxin for pain management: insights from animal models.

Authors:  Flaminia Pavone; Siro Luvisetto
Journal:  Toxins (Basel)       Date:  2010-12-21       Impact factor: 4.546

9.  Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.

Authors:  Carrie E Robertson; Ivan Garza
Journal:  Neuropsychiatr Dis Treat       Date:  2012-01-13       Impact factor: 2.570

10.  The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.

Authors:  Sara Marinelli; Valentina Vacca; Ruggero Ricordy; Carolina Uggenti; Ada Maria Tata; Siro Luvisetto; Flaminia Pavone
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.